Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRITICAL: Anti-thymocyte globulin and pegfilgrastim in recent-onset type 1 diabetes
jRCTs031180089Completed
- Sponsor
- National Center for Global Health and Medicine
- Start
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of antithymocyte globulin rabbit and pegfilgrastim in diabetes mellitus type 1 (T1D), sponsored by National Center for Global Health and Medicine. Primary endpoint: Frequency of adverse events during 52 weeks. Started Aug 2019; status: completed.
02
Drugs
antithymocyte globulin rabbitpegfilgrastim
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on jRCTs031180089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180089.